[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JOP20190261A1 - أجسام مضادة لعامل مساعد لـ btla واستخداماتها - Google Patents

أجسام مضادة لعامل مساعد لـ btla واستخداماتها

Info

Publication number
JOP20190261A1
JOP20190261A1 JOP/2019/0261A JOP20190261A JOP20190261A1 JO P20190261 A1 JOP20190261 A1 JO P20190261A1 JO P20190261 A JOP20190261 A JO P20190261A JO P20190261 A1 JOP20190261 A1 JO P20190261A1
Authority
JO
Jordan
Prior art keywords
agonist antibodies
btla agonist
antibodies
btla
agents
Prior art date
Application number
JOP/2019/0261A
Other languages
English (en)
Inventor
Shane Krummen Atwell
Victor H Obungu
Andrew Charles Vendel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of JOP20190261A1 publication Critical patent/JOP20190261A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

يوفر الاختراع الحالي أجسام مضادة تربط BTLA، وطرق استخدامها، تكون الأجسام المضادة المذكورة مفيدة كعوامل لعلاج حالات مرضية ترتبط بمرض ناجم عن المناعة الذاتية يتضمن علاج الذئبة.
JOP/2019/0261A 2017-05-19 2017-06-16 أجسام مضادة لعامل مساعد لـ btla واستخداماتها JOP20190261A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762508510P 2017-05-19 2017-05-19

Publications (1)

Publication Number Publication Date
JOP20190261A1 true JOP20190261A1 (ar) 2019-11-05

Family

ID=62245543

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0261A JOP20190261A1 (ar) 2017-05-19 2017-06-16 أجسام مضادة لعامل مساعد لـ btla واستخداماتها

Country Status (26)

Country Link
US (2) US10604573B2 (ar)
EP (1) EP3625257A1 (ar)
JP (2) JP6790304B2 (ar)
KR (3) KR20220158847A (ar)
CN (3) CN117402244A (ar)
AR (1) AR111752A1 (ar)
AU (2) AU2018269585B2 (ar)
BR (1) BR112019021547A2 (ar)
CA (2) CA3184628A1 (ar)
CL (1) CL2019003215A1 (ar)
CO (1) CO2019012756A2 (ar)
CR (1) CR20190521A (ar)
DO (1) DOP2019000293A (ar)
EA (1) EA201992460A1 (ar)
EC (1) ECSP19082184A (ar)
JO (1) JOP20190261A1 (ar)
MA (1) MA49133A (ar)
MX (1) MX2019013604A (ar)
MY (1) MY197425A (ar)
NZ (1) NZ758360A (ar)
PE (1) PE20191843A1 (ar)
PH (1) PH12019502575A1 (ar)
SA (1) SA519410534B1 (ar)
TW (4) TWI747043B (ar)
WO (1) WO2018213113A1 (ar)
ZA (1) ZA201906954B (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
MX2022004311A (es) 2019-10-15 2022-05-10 Lilly Co Eli Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante.
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
US20230391872A1 (en) * 2020-10-23 2023-12-07 Anaptysbio, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same
MX2024009326A (es) * 2022-01-29 2024-08-06 Hifibio Inc Anticuerpos anti-btla y usos de los mismos en el tratamiento del cancer.
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546541B2 (en) * 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
EP1560593B1 (en) * 2002-10-25 2016-04-20 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
NZ577085A (en) * 2006-11-15 2012-06-29 Medarex Inc Human monoclonal antibodies to btla and methods of use
EA201270228A1 (ru) * 2009-07-31 2012-09-28 Медарекс, Инк. Полноценные человеческие антитела к btla
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
WO2014018931A1 (en) * 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
US10005839B2 (en) * 2013-05-17 2018-06-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antagonist of the BTLA/HVEM interaction for use in therapy
US11352428B2 (en) * 2015-04-29 2022-06-07 Sanford Burnham Prebys Medical Discovery Institute Modulation of immune response using BTLA agonist antibodies
EP3383908A1 (en) * 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)

Also Published As

Publication number Publication date
MA49133A (fr) 2020-03-25
TWI677504B (zh) 2019-11-21
TWI804044B (zh) 2023-06-01
WO2018213113A1 (en) 2018-11-22
JP2020518288A (ja) 2020-06-25
KR102294051B1 (ko) 2021-08-27
BR112019021547A2 (pt) 2020-05-12
KR20220158847A (ko) 2022-12-01
EP3625257A1 (en) 2020-03-25
SA519410534B1 (ar) 2023-11-08
US20200239578A1 (en) 2020-07-30
CN117402245A (zh) 2024-01-16
CR20190521A (es) 2020-01-06
TW202334237A (zh) 2023-09-01
ZA201906954B (en) 2021-06-30
US11396545B2 (en) 2022-07-26
TW202233681A (zh) 2022-09-01
ECSP19082184A (es) 2019-11-30
PE20191843A1 (es) 2019-12-31
US20180334502A1 (en) 2018-11-22
AU2018269585A1 (en) 2019-10-31
JP7072622B2 (ja) 2022-05-20
TW201946932A (zh) 2019-12-16
JP6790304B2 (ja) 2020-11-25
DOP2019000293A (es) 2019-12-15
TWI747043B (zh) 2021-11-21
MX2019013604A (es) 2019-12-18
CA3184628A1 (en) 2018-11-22
KR20190140969A (ko) 2019-12-20
MY197425A (en) 2023-06-16
TW201904991A (zh) 2019-02-01
CN110621699A (zh) 2019-12-27
AR111752A1 (es) 2019-08-14
CO2019012756A2 (es) 2020-01-17
AU2018269585B2 (en) 2021-09-02
JP2021019642A (ja) 2021-02-18
CL2019003215A1 (es) 2020-04-13
PH12019502575A1 (en) 2020-07-13
CN110621699B (zh) 2023-10-31
US10604573B2 (en) 2020-03-31
CN117402244A (zh) 2024-01-16
EA201992460A1 (ru) 2020-03-18
KR20210106033A (ko) 2021-08-27
NZ758360A (en) 2022-10-28
AU2021277743A1 (en) 2021-12-23
CA3064518A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
PH12019502575A1 (en) Btla agonist antibodies and uses thereof
MX2020012562A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12019500929A1 (en) Anti il-33 antibodies and uses thereof
PE20191812A1 (es) Compuestos y metodos para la reduccion celular especifica de tumor
MX2017014955A (es) Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
MX2023002588A (es) Anticuerpos anti-tgf-beta y su uso.
MX2018003629A (es) Anticuerpos anti-pd1 y metodos de uso.
EP3954713A3 (en) Bispecific antibodies that bind to cd38 and cd3
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
WO2018075820A3 (en) Cereblon-based heterodimerizable chimeric antigen receptors
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
MX2023010076A (es) Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
IL276746A (en) Kir3dl3 as hhla2 receptor, anti-hhla2 antibodies and their uses
PH12016501341A1 (en) Non-human animals having humanized fc-gamma receptors
PH12019501605A1 (en) Glucagon receptor binding proteins and methods of use thereof
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2023006786A (es) Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.
MX2019005933A (es) Polipeptidos biespecificos para gitr y ctla-4.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
MX2019002349A (es) Anticuerpos inmunomoduladores biespecíficos que se fijan a receptores coestimuladores y de puntos de control.
EA201892257A1 (ru) Анти-cd3 антитела и способы применения